tiprankstipranks
Trending News
More News >
TG Therapeutics (TGTX)
NASDAQ:TGTX
US Market
Advertisement

TG Therapeutics (TGTX) Stock Forecast & Price Target

Compare
2,058 Followers
See the Price Targets and Ratings of:

TGTX Analyst Ratings

Hold
3Ratings
Hold
1 Buy
1 Hold
1 Sell
Based on 3 analysts giving stock ratings to
TG
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TGTX Stock 12 Month Forecast

Average Price Target

$32.67
▲(17.14% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for TG Therapeutics in the last 3 months. The average price target is $32.67 with a high forecast of $50.00 and a low forecast of $11.00. The average price target represents a 17.14% change from the last price of $27.89.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","51":"$51","20.25":"$20.3","30.5":"$30.5","40.75":"$40.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,20.25,30.5,40.75,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.02,36.1723076923077,37.324615384615385,38.47692307692308,39.62923076923077,40.78153846153846,41.933846153846154,43.08615384615385,44.238461538461536,45.39076923076923,46.543076923076924,47.69538461538461,48.847692307692306,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.02,34.839230769230774,34.658461538461545,34.47769230769231,34.29692307692308,34.11615384615385,33.93538461538462,33.754615384615384,33.573846153846155,33.393076923076926,33.2123076923077,33.03153846153846,32.85076923076923,{"y":32.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.02,33.1723076923077,31.324615384615388,29.47692307692308,27.629230769230773,25.781538461538464,23.933846153846154,22.08615384615385,20.23846153846154,18.39076923076923,16.543076923076924,14.695384615384615,12.847692307692306,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.93,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.49,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.83,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.09,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.1,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.75,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.37,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.02,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$50.00Average Price Target$32.67Lowest Price Target$11.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on TGTX
TipRanks AITipRanks
Not Ranked
TipRanks
$30
Hold
7.57%
Upside
Reiterated
08/05/25
The overall score reflects strong earnings call insights and financial performance, tempered by bearish technical signals and high valuation concerns. The company shows promise with significant revenue growth and strategic initiatives, but risks remain due to cash flow challenges and current market momentum.
TD Cowen
$50
Buy
79.28%
Upside
Reiterated
08/04/25
TG Therapeutics: Strong Market Position and Growth Prospects Make It an Attractive Buy
Bank of America Securities Analyst forecast on TGTX
Alec StranahanBank of America Securities
Bank of America Securities
$11
Sell
-60.56%
Downside
Reiterated
08/04/25
Bank of America Securities Reaffirms Their Sell Rating on TG Therapeutics (TGTX)
Goldman Sachs Analyst forecast on TGTX
Corinne JohnsonGoldman Sachs
Goldman Sachs
$37
Hold
32.66%
Upside
Initiated
07/10/25
TG Therapeutics (TGTX) Gets a Hold from Goldman Sachs
J.P. Morgan Analyst forecast on TGTX
Eric JosephJ.P. Morgan
J.P. Morgan
$46
Buy
64.93%
Upside
Reiterated
05/05/25
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), TG Therapeutics (NASDAQ: TGTX) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Jefferies Analyst forecast on TGTX
Roger SongJefferies
Jefferies
$46
Buy
64.93%
Upside
Reiterated
05/05/25
Jefferies reiterates Buy Rating on TG Therapeutics (TGTX)Jefferies analyst Roger Song reiterated a Buy rating and $46.00 price target on TG Therapeutics (NASDAQ: TGTX).
H.C. Wainwright Analyst forecast on TGTX
Edward WhiteH.C. Wainwright
H.C. Wainwright
$55
Buy
97.20%
Upside
Reiterated
04/08/25
Buy Rating for TG Therapeutics Driven by Promising Briumvi Data and Strong Revenue Projections
Cantor Fitzgerald Analyst forecast on TGTX
Prakhar AgrawalCantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
03/03/25
Cantor Fitzgerald reiterates Overweight Rating on TG Therapeutics (TGTX)Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on TG Therapeutics (NASDAQ: TGTX).
B.Riley Financial Analyst forecast on TGTX
Mayank MamtaniB.Riley Financial
B.Riley Financial
$38$53
Buy
90.03%
Upside
Reiterated
03/03/25
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (NASDAQ: TGTX), BioLife Solutions (NASDAQ: BLFS) and Surgery Partners (NASDAQ: SGRY)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on TGTX
TipRanks AITipRanks
Not Ranked
TipRanks
$30
Hold
7.57%
Upside
Reiterated
08/05/25
The overall score reflects strong earnings call insights and financial performance, tempered by bearish technical signals and high valuation concerns. The company shows promise with significant revenue growth and strategic initiatives, but risks remain due to cash flow challenges and current market momentum.
TD Cowen
$50
Buy
79.28%
Upside
Reiterated
08/04/25
TG Therapeutics: Strong Market Position and Growth Prospects Make It an Attractive Buy
Bank of America Securities Analyst forecast on TGTX
Alec StranahanBank of America Securities
Bank of America Securities
$11
Sell
-60.56%
Downside
Reiterated
08/04/25
Bank of America Securities Reaffirms Their Sell Rating on TG Therapeutics (TGTX)
Goldman Sachs Analyst forecast on TGTX
Corinne JohnsonGoldman Sachs
Goldman Sachs
$37
Hold
32.66%
Upside
Initiated
07/10/25
TG Therapeutics (TGTX) Gets a Hold from Goldman Sachs
J.P. Morgan Analyst forecast on TGTX
Eric JosephJ.P. Morgan
J.P. Morgan
$46
Buy
64.93%
Upside
Reiterated
05/05/25
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), TG Therapeutics (NASDAQ: TGTX) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Jefferies Analyst forecast on TGTX
Roger SongJefferies
Jefferies
$46
Buy
64.93%
Upside
Reiterated
05/05/25
Jefferies reiterates Buy Rating on TG Therapeutics (TGTX)Jefferies analyst Roger Song reiterated a Buy rating and $46.00 price target on TG Therapeutics (NASDAQ: TGTX).
H.C. Wainwright Analyst forecast on TGTX
Edward WhiteH.C. Wainwright
H.C. Wainwright
$55
Buy
97.20%
Upside
Reiterated
04/08/25
Buy Rating for TG Therapeutics Driven by Promising Briumvi Data and Strong Revenue Projections
Cantor Fitzgerald Analyst forecast on TGTX
Prakhar AgrawalCantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
03/03/25
Cantor Fitzgerald reiterates Overweight Rating on TG Therapeutics (TGTX)Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on TG Therapeutics (NASDAQ: TGTX).
B.Riley Financial Analyst forecast on TGTX
Mayank MamtaniB.Riley Financial
B.Riley Financial
$38$53
Buy
90.03%
Upside
Reiterated
03/03/25
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (NASDAQ: TGTX), BioLife Solutions (NASDAQ: BLFS) and Surgery Partners (NASDAQ: SGRY)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering TG Therapeutics

1 Month
xxx
Success Rate
22/32 ratings generated profit
69%
Average Return
+12.26%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 68.75% of your transactions generating a profit, with an average return of +12.26% per trade.
3 Months
xxx
Success Rate
18/28 ratings generated profit
64%
Average Return
+21.98%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +21.98% per trade.
1 Year
Edward WhiteH.C. Wainwright
Success Rate
21/28 ratings generated profit
75%
Average Return
+84.11%
reiterated a buy rating 4 months ago
Copying Edward White's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +84.11% per trade.
2 Years
xxx
Success Rate
24/28 ratings generated profit
86%
Average Return
+107.64%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +107.64% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TGTX Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
3
3
1
0
1
Buy
4
7
4
4
1
Hold
1
5
5
13
10
Sell
0
0
0
0
0
Strong Sell
4
4
3
2
2
total
12
19
13
19
14
In the current month, TGTX has received 2 Buy Ratings, 10 Hold Ratings, and 2 Sell Ratings. TGTX average Analyst price target in the past 3 months is 32.67.
Each month's total comprises the sum of three months' worth of ratings.

TGTX Financial Forecast

TGTX Earnings Forecast

Next quarter’s earnings estimate for TGTX is $0.22 with a range of $0.11 to $0.33. The previous quarter’s EPS was $0.17. TGTX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.46% of the time in the same period. In the last calendar year TGTX has Preformed in-line its overall industry.
Next quarter’s earnings estimate for TGTX is $0.22 with a range of $0.11 to $0.33. The previous quarter’s EPS was $0.17. TGTX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.46% of the time in the same period. In the last calendar year TGTX has Preformed in-line its overall industry.

TGTX Sales Forecast

Next quarter’s sales forecast for TGTX is $152.25M with a range of $147.67M to $157.50M. The previous quarter’s sales results were $141.15M. TGTX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 48.05% of the time in the same period. In the last calendar year TGTX has Outperformed its overall industry.
Next quarter’s sales forecast for TGTX is $152.25M with a range of $147.67M to $157.50M. The previous quarter’s sales results were $141.15M. TGTX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 48.05% of the time in the same period. In the last calendar year TGTX has Outperformed its overall industry.

TGTX Stock Forecast FAQ

What is TGTX’s average 12-month price target, according to analysts?
Based on analyst ratings, TG Therapeutics’s 12-month average price target is 32.67.
    What is TGTX’s upside potential, based on the analysts’ average price target?
    TG Therapeutics has 17.14% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TGTX a Buy, Sell or Hold?
          TG Therapeutics has a consensus rating of Hold which is based on 1 buy ratings, 1 hold ratings and 1 sell ratings.
            What is TG Therapeutics’s price target?
            The average price target for TG Therapeutics is 32.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $50.00 ,the lowest forecast is $11.00. The average price target represents 17.14% Increase from the current price of $27.89.
              What do analysts say about TG Therapeutics?
              TG Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of TGTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis